Docs were shocked that lowering Lp(a) didn’t slash heart risks. Here’s what to know.

A nationwide Danish study of more than 132,000 people found a strong association between participants who took a popular ...

Arterial calcium buildup can signal underlying plaque and cardiovascular risk, showing why heart health involves more than ...

Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks ...

A single dose of an experimental jab has been found to cut "bad" cholesterol levels by half within six months of treatment in ...

Most people need to take statins for a long time, and for some, the rest of their lives. According to experts, cholesterol ...

Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia.

A new fruit that has landed in Tesco, M&S and Ocado for a limited time could help people trying to manage their high ...

Researchers have designed a new DNA-based treatment that targets PCSK9, a protein closely tied to high LDL cholesterol and ...

Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing ‌a blow ...

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...

The findings suggest that breastfeeding may offer mothers with previous gestational diabetes an additional metabolic benefit ...